INVESTMENT SECURITIES |
12 Months Ended |
---|---|
Sep. 30, 2022 | |
Disclosure Investment Securities Abstract | |
INVESTMENT SECURITIES | NOTE 10. INVESTMENT SECURITIES During the quarter ended June 30, 2021 the Company was paid 50,000 common shares of Oncology Pharma, Inc. pursuant to an agreement entered into by and between KCL Therapeutics, Inc. ( a wholly owned subsidiary of the Company) and Oncology Pharma, Inc. whereby Oncology Pharma, Inc. was granted a license for the development and commercialization of certain intellectual property (“License IP”) for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021. During the quarter ended June 30, 2021 of the aforementioned common shares were sold to an unrelated party for $ cash. During
the quarter ended September 30, 2021 During the quarter ended September 30, 2022 25,000 cash. of the aforementioned common shares were sold to Zander Therapeutics, Inc. ( company under common control with Regen) for consideration consisting of $ |